WebNov 26, 2024 · The exchange’s momentum could be attributed to listing reforms introduced in 2024 that allowed pre-revenue biotech companies to raise funding through a path called Chapter 18A, which, among other things, requires biotech applicants to have at least two years of operations in the same line of business and an initial market capitalization of ... WebIn addition, Chapter 18A imposes disclosure requirements specific to Biotech Companies. In April 2024, the Stock Exchange also released Guidance Letter HKEX-GL107-205, which provides further guidance on disclosure in listing documents for Biotech Companies.
An Easier Road to a Hong Kong Listing for Biotech Companies
WebJun 29, 2024 · Since the introduction of Chapter 18A in 2024, which allows listing for pre-revenue biotech companies, the HKEx has cultivated the development of a viable eco system for fundraising of healthcare and life sciences companies, which has generated a steady flow of listings of biotech companies. Weband the retail market toward Chapter 18A over the past two years. To further develop this chapter and the biotech ecosystem in Hong Kong, on 30 April 2024 the HKEX published new and updated guidance letters for pre-revenue biotech companies, providing prospective issuers and the market with more clarity on the requirements for listing and required can you buy a fennec fox as a pets
2024 HKEX Biotech Listings Drop from Last Year’s Record High
WebJul 10, 2024 · HKEx further clarifies that (i) an existing shareholder holding less than 10% of the shares in the biotech company may subscribe for shares in the IPO as either a cornerstone investor or as a... WebJul 3, 2024 · HKEX closed 2024 with a total of 92 biotech and healthcare listings on its main board, raising a total of HKD 255 billion (USD 32.6 billion) since the launch of the internal reforms. The figure includes 48 pre-revenue biotech companies that have listed under Chapter 18A, raising a total of HKD 112.6 billion (USD 14.4 billion). WebApr 13, 2024 · Being approved to drop the "B" marker from its stock short name indicates that a biotech company listed at the HKEX under Chapter 18A of the listing rules has met higher standards for revenue, market cap, etc. ... Shortly after the company was listed on the main board of the HKEX on December 30, 2024, it was included in the Shanghai-Hong … briggs and stratton intek horizontal engine